drugset / Trial / NCT02473016

Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia

NCT02473016

Phase 2 Completed 30 enrolled Capnia, Inc.
CrossoverSingle-blindTreatment

Summary

A placebo-controlled, single-blind study to evaluate the safety and preliminary efficacy of nasal carbon dioxide for the symptomatic treatment of classical trigeminal neuralgia.

Timeline

Start
2015-09
Primary completion
2017-03
Completion
2017-04

Drugs

EvaluationDrugModalityDoseRoute
Subject carbon dioxide Other / unclassified Intranasal

Indications